THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.27] ID: TIP-MED-000459 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Adapalene, Benzoyl Peroxide & Oral Isotretinoin

Active Ingredient / Scientific Identity: Adapalene, Benzoyl Peroxide & Oral Isotretinoin • Class: Third-Generation Topical Retinoid, Bactericidal Oxidising Comedolytic & Systemic Retinoid for Acne Vulgaris (Schedule H | NLEM 2022 [Benzoyl Peroxide] | HIGH-ALERT TERATOGEN [Isotr.

⚖️ Compare Profile
Generic / Entity NameAdapalene, Benzoyl Peroxide & Oral Isotretinoin ([12.27])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassThird-Generation Topical Retinoid, Bactericidal Oxidising Comedolytic & Systemic Retinoid
Available Dosage FormsStandard hospital formulary strengths
Regulatory ClassificationSchedule H (Prescription Only — Registered Medical Practitioner)
Key Warning & Review DateHigh-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H (Prescription Only — Registered Medical P🚨 Clinically High-Alert: Independent Dose & Route Verification Required☣️ Hazardous / Reproductive Precaution: Strict Handling & Contraception Protocol👨‍⚕️ Specialist-Supervised Therapy

1. Clinical & Scientific Overview

Adapalene, Benzoyl Peroxide & Oral Isotretinoin (TIP-MED-000459, Reference Code [12.27]) is classified under Dermatological Preparations as a Third-Generation Topical Retinoid, Bactericidal Oxidising Comedolytic & Systemic Retinoid for Acne Vulgaris (Schedule H | NLEM 2022 [Benzoyl Peroxide] | HIGH-ALERT TERATOGEN [Isotr.. Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Registered Medical Practitioner).

Verified Indian Market Examples / Compendial Status:
Representative Indian Formulations (for identification only): Adapalene 0.1%: Adaferin (Galderma), Deriva-CMS (Glenmark); FDCs: Deriva-BPO / Epiduo (Adapalene 0.1% + Benzoyl Peroxide 2.5% — Antibiotic-Free!), Deriva-C (+ Clindamycin 1%). | Strengths: Adapalene Aqueous Microsphere Gel: **0.1% w/w** (15 g). Benzoyl Peroxide Gel/Wash: **2.5%**, 5% w/w (2.5% is equally effective as 5%/10% with 50% less skin irritation!). Oral Isotretinoin Softgel Capsules: **10 mg, 20 mg, 30 mg**
Representative Indian Formulations (for identification only): Adapalene 0.1%: Adaferin (Galderma), Deriva-CMS (Glenmark); FDCs: Deriva-BPO / Epiduo (Adapalene 0.1% + Benzoyl Peroxide 2.5% — Antibiotic-Free!), Deriva-C (+ Clindamycin 1%). | Strengths: Adapalene Aqueous Microsphere Gel: **0.1% w/w** (15 g). Benzoyl Peroxide Gel/Wash: **2.5%**, 5% w/w (2.5% is equally effective as 5%/10% with 50% less skin irritation!). Oral Isotretinoin Softgel Capsules: **10 mg, 20 mg, 30 mg**
Dosage Forms & Available Strengths:
Standard hospital formulary strengths
Routes: Intravenous / Parenteral / Oral

3. Mechanism of Action & Pharmacodynamics

Established pharmacological class action (Third-Generation Topical Retinoid, Bactericidal Oxidising Comedolytic & Systemic Retinoid for Acne Vulgaris (Schedule H | NLEM 2022 [Benzoyl Peroxide] | HIGH-ALERT TERATOGEN [Isotr.): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Adapalene 0.

4. Therapeutic Indications & Evidence-Supported Uses

  • Adapalene 0
  • 1% & Benzoyl Peroxide 2
  • 5%: First-line topical therapy for mild-to-moderate comedonal (blackheads/whiteheads) and papulopustular **Acne Vulgaris** (**Adapalene 0
  • 1% + BPO 2
  • 5% [Deriva-BPO / Epiduo]** normalises follicular keratinisation and kills *Cutibacterium acnes* via free-radical oxidation with **ZERO

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Topical Adapalene 0.1% / Deriva-BPO: Wash face with mild cleanser, wait 15–20 min until skin is completely dry, and apply a **SINGLE PEA-SIZED DOT** to the **ENTIRE acne-prone face** (forehead, cheeks, chin — NOT just individual pimples; (Duration: Topical Acne: **8 to 12 weeks** minimum (warn patient that early microcomedone purging in Weeks 2–4 is normal and full clearing takes 8–12 weeks!). Oral Isotretinoin: 16–24 weeks)

Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified), Topical / Cutaneous | Food & Meal Timing: Topical Adapalene: Apply at **BEDTIME** (retinoids increase UV sensitivity) and apply a non-comedogenic moisturiser + morning **SPF 30–50+ Sunscreen**! Oral Isotretinoin: Swallow softgel capsules whol. | Best Time of Day: Topical Adapalene: Bedtime (OD). Benzoyl Peroxide: Morning (or at Bedtime in Adapalene+BPO FDC). Oral Isotretinoin: With Lunch/Dinner

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Metabolism & Biotransformation:
Renal & Hepatic: Oral Isotretinoin is contraindicated in hepatic insufficiency and severe hyperlipidaemia
Elimination & Renal Adjustment:
Renal & Hepatic: Oral Isotretinoin is contraindicated in hepatic insufficiency and severe hyperlipidaemia
Hepatic Impairment Considerations:
Renal & Hepatic: Oral Isotretinoin is contraindicated in hepatic insufficiency and severe hyperlipidaemia

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • ABSOLUTE HUMAN TERATOGENICITY BOXED WARNING FOR ORAL ISOTRETINOIN (AND TOPICAL RETINOIDS IN PREGNANCY!): **Oral Isotretinoin is one of the most potent human teratogens known** — even a **SINGLE CAPSULE** taken during pregnancy carries a 25%–40% risk of catastrophic birth defects (**Craniofacial/Ear absence [anotia], Conotruncal Heart Defe

Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Topical Adapalene & BPO: Mild erythema, peeling/scaling, dryness, and stinging during the first 2–4 weeks ('retinoid dermatitis' — managed by applying moisturiser first ['sandwich method'] and spacing to alternate nights)
Serious / Dose-Limiting Adverse Effects:
  • Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CRITICAL ORAL ISOTRETINOIN CONTRAINDICATED INTERACTIONS: (1) **TETRACYCLINES (Doxycycline, Minocycline, Tetracycline) + Oral Isotretinoin = STRICTLY CONTRAINDICATED!** Both independently raise intracranial pressure

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.

Pharmacist Patient Counselling Points:

  • SIX VITAL ACNE COUNTER RULES: (1) For Deriva/Epiduo gel: apply ONLY a **single pea-sized dot** across the whole dry face at bedtime (more gel does NOT clear pimples faster — it only burns the skin!), use a moisturiser + morning sunscreen, and wait 8–12 weeks for full results

Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Adapalene Aqueous Microsphere Gel: **0.1% w/w** (15 g). Benzoyl Peroxide Gel/Wash: **2.5%**, 5% w/w (2.5% is equally effective as 5%/10% with 50% less skin irritation!). Oral Isotretinoin Softgel Capsules: **10 mg, 20 mg, 30 mg**). Missed-Dose Rule: Skip if missed; never double dose

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.